Heart:房颤的临床表现和预后有性别差异?

2017-06-16 MedSci MedSci原创

近日,在国际心血管权威杂志《Heart》上发表了一篇大型临床研究,旨在评估房颤患者在临床表现、管理和预后方面的性别差异。

近日,在国际心血管权威杂志《Heart》上发表了一篇大型临床研究,旨在评估房颤患者在临床表现、管理和预后方面的性别差异。

本研究共纳入欧洲房颤注册数据库中的6412名房颤患者,其中女性占39.7%,通过在临床表现、危险因素、治疗手段和1年内不良结局的发生方面进行性别差异的评估。

研究结果显示,男性的房颤患者平均年龄要低于女性患者(mean±SD: 70.1±10.7 vs 74.1±9.7?岁, p<0.0001)。女性患者至少发生一次房颤相关的临床症状频率要高于男性(女性95.4%,男性 89.8%, p<0.0001)。处方的口服抗凝药物相似,非维生素K口服抗凝药的增加在女性患者中从5.9%到12.6%,在男性中从6.2%到12.6%,两者的p值均小于0.0001。此外,男性患者接受电复律和消融的比率较女性更高(男性分别是20.6%和 6.3%,女性分别是14.9%和3.3%),p<0.0001。在女性房颤患者中,冠脉血运重率要低65%(OR: 0.35; 95% CI (0.22 to 0.56)),1年的急性冠脉综合征发生率低40%(OR: 0.60; (0.38 to 0.93)),1年的心衰发生率要低20%(OR: 0.80; (0.68 to 0.96))。在1年的中风、短暂性脑缺血发作、动脉血栓栓塞和大出血事件的发生中,性别之间无统计学差异。

在本研究中,女性的房颤患者的临床表现症状更明显,但是接受电复律和消融的概率要更低。

原始出处:

Doi:http://dx.doi.org/10.1136/heartjnl-2016-310406

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=212636, encodeId=1d6d212636dd, content=学习了,分享了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Mon Jun 19 07:24:20 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356346, encodeId=cfdd135634602, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 18 02:03:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562579, encodeId=f40315625e9be, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jun 18 02:03:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211988, encodeId=9669211988ec, content=学习了,提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sat Jun 17 17:08:49 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-19 杨利洪

    学习了,分享了。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=212636, encodeId=1d6d212636dd, content=学习了,分享了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Mon Jun 19 07:24:20 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356346, encodeId=cfdd135634602, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 18 02:03:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562579, encodeId=f40315625e9be, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jun 18 02:03:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211988, encodeId=9669211988ec, content=学习了,提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sat Jun 17 17:08:49 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-18 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=212636, encodeId=1d6d212636dd, content=学习了,分享了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Mon Jun 19 07:24:20 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356346, encodeId=cfdd135634602, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 18 02:03:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562579, encodeId=f40315625e9be, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jun 18 02:03:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211988, encodeId=9669211988ec, content=学习了,提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sat Jun 17 17:08:49 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-18 slcumt
  4. [GetPortalCommentsPageByObjectIdResponse(id=212636, encodeId=1d6d212636dd, content=学习了,分享了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Mon Jun 19 07:24:20 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356346, encodeId=cfdd135634602, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 18 02:03:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562579, encodeId=f40315625e9be, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Sun Jun 18 02:03:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211988, encodeId=9669211988ec, content=学习了,提高了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/21/39b6a0099eb602e8ac1f7e10d5d440a9.jpg, createdBy=dee01724555, createdName=杨利洪, createdTime=Sat Jun 17 17:08:49 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 杨利洪

    学习了,提高了

    0

相关资讯

Circulation:microRNA-146a在心衰的氧化代谢中起到关键作用!

心血管疾病仍然是世界死亡的主要原因,心衰的发病率也在逐年上升。尽管心衰的代谢改变渐渐被学者们发现,但针对这些代谢改变的治疗方法仍缺乏。

Nature Biomedical Engineering:3D打印将细胞排列成特定图案,为损伤血管打“补丁”

血管狭窄、硬化或者堵塞引起的组织缺血经常导致心脏病发作,中风,坏疽等严重疾病。虽然目前的手术可以修复大血管出现的问题,但治疗那些比较微小或已被治疗损伤过的血管仍然十分复杂。近日,来自波士顿大学等机构的研究人员开发一种新方法,利用注入内皮细胞的3D打印血管补片,生长出健康血管。该研究发表在新一期的Nature Biomedical Engineering期刊上。

坎格列净减少心血管事件,增加截肢风险——CANVAS研究结果公布

CANVAS研究结果的公布,将2017年ADA年会的气氛推向高潮。一如预期,该研究结果显示,新型降糖药物SGLT-2抑制剂坎格列净治疗可以显着降低受试者主要复合心血管终点事件发生率。然而,本研究同时发现该药明显增加了截肢风险。

SCI REP:心房颤动作为心肌梗死和心血管死亡的预后指标!

这些结果表明心房颤动是心肌梗死、心血管死亡和心血管事件的独立危险因素。

Heart:BP-BES植入术后远期(8-10年)的随访结果出炉!

目前,对于生物可降解聚合物包被的生物膜洗脱支架(BP-BES)植入后的有效性和安全性随访数据仅限于5年。本研究旨在评估BP-BES植入后远期的(8-10年)的临床和血管造影随访的数据资料。

ADA 2017:DEVOTE研究证实德谷胰岛素具有心血管安全性且严重低血糖大幅减少

6月12日,心血管安全性终点研究DEVOTE在ADA2017重磅公布,该研究首次头对头比较了两种基础胰岛素——德谷胰岛素和甘精胰岛素U100在2型糖尿病患者中的心血管安全性。结果证实,新型超长效胰岛素制剂德谷胰岛素的心血管安全性与甘精胰岛素U100相当,但较甘精胰岛素U100显着降低了40%的严重低血糖,夜间严重低血糖显着降低53%。